Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 7;13(7):2138.
doi: 10.3390/jcm13072138.

Trifecta Outcomes of Robot-Assisted Partial Nephrectomy Using the New Hugo™ RAS System Versus Laparoscopic Partial Nephrectomy

Affiliations

Trifecta Outcomes of Robot-Assisted Partial Nephrectomy Using the New Hugo™ RAS System Versus Laparoscopic Partial Nephrectomy

Francesco Prata et al. J Clin Med. .

Abstract

(1) Background: Laparoscopic partial nephrectomy (LPN) is still performed in many referred urological institutions, representing a valid alternative to robot-assisted partial nephrectomy (RAPN). We aimed to compare trifecta outcomes of LPN and RAPN with the Hugo™ RAS System. (2) Methods: Between October 2022 and September 2023, eighty-nine patients underwent minimally invasive partial nephrectomy (group A, RAPN = 27; group B, Laparoscopic PN = 62) for localized renal tumors at our Institution. Continuous variables were presented as median and IQR and compared by means of the Mann-Whitney U test, while categorical variables were presented as frequencies (%) and compared by means of the χ2 test. (3) Results: Group A showed a higher rate of male patients (81.5% vs. 59.7%, p = 0.04) and a higher trend towards larger clinical tumor size (34 vs. 29 mm, p = 0.14). All the other baseline variables were comparable between the two groups (all p > 0.05). Regarding post-operative data, group A displayed a lower operative time (92 vs. 149.5 min, p = 0.005) and a shorter hospital stay (3 vs. 5, p = 0.002). A higher rate of malignant pathology was evidenced in group A (77.8% vs. 58.1%, p = 0.07) as well as a lower trend towards positive surgical margins (3.7% vs. 4.8%, p = 0.82), even if not statistically significant. (4) Conclusions: The rate of trifecta achievement was 92.6% and 82.3% for group A and B (p = 0.10), respectively. In terms of trifecta outcomes, RAPN using the Hugo™ RAS System showed comparable results to LPN performed by the same experienced surgeon.

Keywords: Hugo RAS; laparoscopic surgery; partial nephrectomy; robotic surgery; trifecta.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Surgical robotic set-up: trocar position and arm carts triangulation.

Similar articles

Cited by

References

    1. Bukavina L., Bensalah K., Bray F., Carlo M., Challacombe B., Karam J.A., Kassouf W., Mitchell T., Montironi R., O’Brien T., et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur. Urol. 2022;82:529–542. doi: 10.1016/j.eururo.2022.08.019. - DOI - PubMed
    1. Campi R., Sessa F., Corti F., Carrion D.M., Mari A., Amparore D., Mir M.C., Fiori C., Papalia R., Kutikov A., et al. Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: A systematic review. Minerva Urol. Nefrol. 2020;72:389–407. doi: 10.23736/S0393-2249.20.03870-9. - DOI - PubMed
    1. Napolitano L., Orecchia L., Giulioni C., Carbonara U., Tavella G., Lizzio L., Fimognari D., De Palma A., Gheza A., Grosso A.A., et al. The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature. Appl. Sci. 2023;13:275. doi: 10.3390/app13010275. - DOI
    1. Marchioni M., Rivas J.G., Autran A., Socarras M., Albisinni S., Ferro M., Schips L., Scarpa R.M., Papalia R., Esperto F. Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art. Curr. Urol. Rep. 2021;22:31. doi: 10.1007/s11934-021-01050-0. - DOI - PMC - PubMed
    1. Petrozza V., Pastore A.L., Palleschi G., Tito C., Porta N., Ricci S., Marigliano C., Costantini M., Simone G., Di Carlo A., et al. Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma. Oncotarget. 2017;8:69551–69558. doi: 10.18632/oncotarget.18449. - DOI - PMC - PubMed

LinkOut - more resources